Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 5/20 | 0.43 |
| ▸ | NMT2 | O60551 | 4/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 4/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122465 | 0.90 | GRIN2D (0.42) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL676216 | 0.87 | GRIN2D (0.43) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1650994 | 0.86 | NMT2 (0.40) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2192122 | 0.84 | FOLH1 (0.38) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL29590333 | 0.81 | FOLH1 (0.44) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30578963 | 0.80 | ERAP2 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30512635 | 0.79 | BACE1 (0.46) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30242246 | 0.78 | FOLH1 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2182926 | 0.78 | OPRK1 (0.42) | NMT1NMT2ERAP2ERAP1LNPEP | |
| SCHEMBL2195069 | 0.78 | OPRK1 (0.42) | NMT1NMT2ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | NMT1 139/4885NMT2 188/4885GRIN2D 4006/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | NMT1 139/4885NMT2 188/4885GRIN2D 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.